linjc16/ctgov huggingface dataset:
Improvement of Appendix Identification and Appendicitis Diagnosis in us After Administration of Oral Contrast Medium

Study Overview
=================
Brief Summary
-----------------
Rate of appendix localization on ultrasound is not high. We suggest a way to improve it's localization by oral administration of iodinated contrast material.

Detailed Description
-----------------
The administration of oral iodinated contrast material might facilitate identification of the appendix and accurate diagnosis of appendicitis. When indicated will shorten time to CT examination.

Official Title
-----------------
Improvement of Appendix Identification and Appendicitis Diagnosis in Ultrasound After Administration of Iodinated Oral Contrast Medium

Conditions
-----------------
Appendicitis

Intervention / Treatment
-----------------
* Other: oral iodinated contrast material


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients in emergency department with right lower quadrant pain Exclusion Criteria: patients under 18 years old pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: oral contrast<br>oral iodinated contrast material | Other: oral iodinated contrast material<br>* diluted in water<br>* Other names: telebrix 35;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Appendix identification rate on ultrasound | Positive identification of the appendix by ultrasound croteria | At the time of ultrasound examination up to 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improved rate of correctly diagnosed appendicitis | Results acording to surgery or patholoy reports | At time of surgery or patholoy results if available within 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ultrasound, iodinated contrast material, computed tomography
Comparison of Perioperative Outcome Between Monopolar and Bipolar Hysteroscopic Myomectomy

Study Overview
=================
Brief Summary
-----------------
Objective: To evaluate clinical outcome between monopolar and bipolar hysteroscopic myomectomy.

Detailed Description
-----------------
Methods: Hysteoscopic myomectomy is a safe and effective procedure to remove submucosal myoma. Distension media is needed to distend the uterine cavity during the procedure. The electric cutting loops included monopolar and bipolar electrodes, and have their corresponding distension media. Medical records, including outpatient and inpatient records, operation note, and laboratory data, of all consecutive women who received hysteroscopic myomectomy between July 2008 and April 2022 will be reviewed. Expected result: The investigatorscan get the differences between monopolar and bipolar hysteroscopic myomectomy, and the result can be used as a reference in clinical practice.

Official Title
-----------------
Comparison of Perioperative Outcome Between Monopolar and Bipolar Hysteroscopic Myomectomy

Conditions
-----------------
Hysteroscopic Myomectomy

Intervention / Treatment
-----------------
* Procedure: Bipolar hysteroscopic myomectomy
* Procedure: Monopolar hysteroscopic myomectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women who received hysteroscopic myomectomy between July 2008 and April 2022 will be reviewed. Exclusion Criteria: < 20 years old women Cervical fibroids were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| monopolar<br>monopolar electrodes, and have their corresponding distension media. | Procedure: Monopolar hysteroscopic myomectomy<br>* Monopolar hysteroscopic myomectomy<br>|
| bipolar<br>bipolar electrodes, and have their corresponding distension media. | Procedure: Bipolar hysteroscopic myomectomy<br>* Bipolar hysteroscopic myomectomy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infused volume of distension medium | The differences of infused volume of distension medium | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operation time | The between-group difference in operation time | 3 months | 
| Pain score after the procedure | The between-group difference in pain score after the procedure Pain score:0-10, the minimun values mean a better | 3 months |
Re-linkage to Care of Patients With Hepatitis C

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify patients with chronic hepatitis C virus (HCV) who were lost of follow up and relinkage them to hepatitis C care

Detailed Description
-----------------
The investigators will review electronic medical charts to identify patients with HCV diagnosis. Next, investigators will evaluate if these patients are routinely followed by liver specialists at the Institution. Those patients who were lost of follow up will be reached to evaluate their disease and eventually offer them to restart HCV care.

Official Title
-----------------
Effectiveness of Implementing a Strategy to Re-linkage to Care of Patients With Hepatitis C Who Were Lost to Follow-up

Conditions
-----------------
Viral Hepatitis C

Intervention / Treatment
-----------------
* Other: Patients with hepatitis C lost follow up


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years Patients clinically evaluated at least once in the participating medical center chronic HCV infection Exclusion Criteria: There are no exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients under routine hepatitis C care<br>Patients who are routinely followed at the treating institution. Investigators will evaluate baseline demographic, liver fibrosis stage, liver-related complications, and antiviral therapy. | |
| Patients with hepatitis C lost of follow-up<br>Patients who were lost of follow-up. Participants will be contacted to evaluate if the continued HCV care at another institution, were not routinely followed by a liver-specialist or if they died. Investigators will also evaluate baseline demographic, liver fibrosis stage, liver-related complications, and antiviral therapy. | Other: Patients with hepatitis C lost follow up<br>* Patients with chronic HCV who were lost of follow up will be contacted by phone or email. At least 3 phone calls will be made on three different days. In case the patient is not contacted it will be considered lost of follow-up<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants who were lost of follow up | Participants are going to be contacted by phone or email to evaluate if they are under HCV care | through study completion, an average of 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
viral infection, outcome, antiviral therapy
Periodontal Inflammation and Immunity in Preclinical Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the association of Rheumatoid Arthritis (RA)-related antibodies and periodontal inflammation in subjects at-risk for Rheumatoid Arthritis. Subjects will undergo periodontal and joint examinations, as well as collection of body fluids to measure Rheumatoid Arthritis-related antibodies.

Official Title
-----------------
Periodontal Inflammation and Immunity in Preclinical Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis, Periodontal Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Rheumatoid Arthritis-antibody positivity (anti-CCP) in the absence of arthritis or Early RA <36 months since diagnosis Exclusion Criteria: Pregnancy Antibiotic use prior to dental procedures or cleanings Wear dentures <18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| At-Risk Rheumatoid Arthritis subjects<br> | |
| Early Rheumatoid Arthritis subjects<br> | |
| Healthy Controls<br> | |
| Non-Rheumatoid Arthritis Autoimmune Controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Degree of periodontal disease by oral examinations according to the American Academy of Periodontology (AAP) guidelines |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of bacterial communities of the periodontium by bacterial diversity (e.g. Shannon Diversity Index) and bacterial load (qPCR) |  | 1 day | 
| Frequency of Rheumatoid Arthritis-related antibodies in blood and mucosal sites using Rheumatoid Factor and Anti-Citrullinated Protein Antibody assays |  | 1 day |
Post Trial Analysis of a Primary Prevention Study in Asian Indians

Study Overview
=================
Brief Summary
-----------------
An extended follow-up study of NCT00819455 conducted 5 years post randomization. In this study we estimate the incidence of type 2 diabetes among participants enrolled in the diabetes prevention programme. This will provide comparison of the progression to diabetes among group motivated through text messages and the group educated only during enrollment. A total of 537 participants were enrolled in the primary study and are invited to participate in a follow-up visit 3 years post active trial period.

Official Title
-----------------
The Role of Information Technology in the Prevention of Type 2 Diabetes - An Extended Follow-up Study

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Behavioral: Text Messaging via Short Message Service


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants of the primary prevention programme - NCT00819455. Exclusion Criteria: Unwilling for participation

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 63 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Intervention - SMS<br>Participants in the intervention group received periodic text messages on healthy lifestyle throughout the study period. | Behavioral: Text Messaging via Short Message Service<br> <br> |
| Control - Standard Care<br>Participants in the control group received standard one time advice at entry in the study. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of type 2 diabetes among participants enrolled in the diabetes prevention programme. |  | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long-term impact of healthy lifestyle through mobile phone based text messaging |  | Two years |
Evaluation Of Valaciclovir In Patients With Chickenpox

Study Overview
=================
Brief Summary
-----------------
This study will assess the safety and efficacy, and the pharmacokinetics of aciclovir and valaciclovir in children with chickenpox following oral administration of valaciclovir, for the purpose of seeking approval of valaciclovir HCl for the treatment of chickenpox.

Official Title
-----------------
Clinical Evaluation of Valaciclovir Hydrochloride: 256U87 in Patients With Chickenpox - Open Uncontrolled Study.

Conditions
-----------------
Varicella

Intervention / Treatment
-----------------
* Drug: valaciclovir HCl granules


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Subjects aged 1 year to less than 12 years with a clinical diagnosis of chickenpox within 48 hours of the onset of the rash. Exclusion criteria: History of hypersensitivity reactions. Impaired hepatic or renal function. Gastrointestinal dysfunction. Serious underlying disease. Weigh over 40kg. Vaccinated for chickenpox.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: valaciclovir HCl granules|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma aciclovir concentrations approximately 1 - 2 hours post-dose, and/or 1, 2, 4 and 6 hours following administration of the valaciclovir HCl granules 25mg/kg -dose. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma valaciclovir concentrations approximately 1 - 2 hours post-dose, and/or 1, 2, 4 and 6 hours following administration of the valaciclovir HCl granules 25mg/kg -dose. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chicken pox, varicella, VZV, pharmacokinetics
Nissen Sleeve by Single Port With Magnetic Assistance

Study Overview
=================
Brief Summary
-----------------
New approach for Nissen Sleeve Gastrectomy by single port using double magnetic system

Detailed Description
-----------------
A bariatric surgery is performed for weight loss and esophagogastric reflux, called Nissen Sleeve, in which a new approach is used which is the only port that helps to shorten the hospital stay because it decreases postoperative pain as well as increases the esthetic Ad benefit. In addition, a system of magnets is used to assist in different steps of the surgery for the correct retraction of the tissues and to be able to suture or perform the correct dissection.

Official Title
-----------------
Double Magnetic-assisted Single-port Nissen Sleeve

Conditions
-----------------
Bariatric Surgery Candidate, Obesity, GERD

Intervention / Treatment
-----------------
* Other: Magnetics Assisted by Singe port


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient with controlled comorbidities suffering from obesity and GERD. Exclusion Criteria: Patients with pacemakers, psychiatric problems or uncontrolled metabolic diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| N-Sleve patients<br>Patient that were selected for surgery | Other: Magnetics Assisted by Singe port<br>* Use of magnet for assistance through the surgery, and a novel approach as it is single port<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgical Complications | any adverse event during the surgery | 1 month | 
| Surgical time | how long does the surgery take | 30 minutes | 
| Weight loss follow up | Kg that the patient loss | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bariatric Surgery, Magnetic assisted, Singe port, Nissen Sleeve
Mechanisms of Stroke in Intracranial Stenosis

Study Overview
=================
Brief Summary
-----------------
The objective of this SAMMPRIS-affiliated study is to understand the mechanisms the mechanisms that underlie ischemic stroke recurrence in high-grade intracranial atherosclerotic disease in order to determine predictors of recurrent stroke. MoSIS will evaluate 6 specific mechanisms of stroke in the medically-treated SAMMPRIS cohort: decreased antegrade flow, progression of stenosis, decreased proximal collateral flow, decreased distal collateral flow, impaired cerebrovascular reserve, and artery-to-artery embolism.

Official Title
-----------------
Mechanisms of Stroke in Intracranial Stenosis and Stenting

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Enrolled in the medical arm of SAMMPRIS, signed consent Exclusion Criteria: For QMRA testing: contraindications to MRI; for TCD testing, abscence of ultrasonographic windows.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ischemic stroke in the territory of the stenotic artery |  | 2 years from enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Symptomatic intracranial atherosclerotic disease enrolled in the medical arm of SAMMPRIS
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.

Official Title
-----------------
A Double-Blind, Randomized, Placebo- and Active-Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women

Conditions
-----------------
Endometrial Hyperplasia, Osteoporosis

Intervention / Treatment
-----------------
* Drug: Bazedoxifene/Conjugate Estrogens (CE)
* Drug: Raloxifene
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Generally healthy, postmenopausal women aged 40 - 75 years inclusive Intact uterus Last natural menstrual cycle (without exogenous hormone therapy) completed at least 12 consecutive months before screening Exclusion Criteria: A history or active presence of thrombophlebitis, thrombosis or thromboembolic disorders A history or active presence of cerebrovascular accident, stroke, or transient ischemic attack A history or active presence of malignancy, or treatment for malignancy, within the previous 10 years Additional criteria applies.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Drug: Bazedoxifene/Conjugate Estrogens (CE)<br> <br> |
| Active Comparator: B<br> | Drug: Raloxifene<br> <br> |
| Placebo Comparator: C<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the effects of Bazedoxifene/Conjugate Estrogens (CE) combinations on the incidence of endometrial hyperplasia in postmenopausal women. |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the efficacy of Bazedoxifene/CE combinations in preventing osteoporosis. To evaluate the effects of Bazedoxifene/CE combinations on vaginal atrophy, metabolic parameters, uterine bleeding, vasomotor symptoms and quality of life indices. |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Menopause
Pharmacogenetics of Antifolate Drugs in Autoimmune Diseases in Taiwan

Study Overview
=================
Brief Summary
-----------------
BACKGROUND. Polymorphisms occur in several genes encoding key enzymes in the folate pathway may affect drug metabolism in patients with rheumatoid arthritis. Whether these genetic variations contribute to differential responses to antifolate drug in patients with rheumatoid arthritis (RA) remains to be investigated in the Taiwanese population. OBJECTIVE. The goal of the present study is to investigate the interactions between genetic variations in folate genes and the efficacy/side effects of anti-folate disease-modifying anti-rheumatic drug in Taiwan. DESIGN. A cross-sectional study involving patients with RA were enrolled from TCVGH. Disease activity, drug efficacy and associated side-effects were assessed. Genotypes in folylpoly-gamma-glutamate synthetase and reduced folate carrier were determined by RFLP or pyrosequencing.

Conditions
-----------------
Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male/female age >18 RA diagnosed Exclusion Criteria: Must not be pregnant/breastfeeding Other conditions may lead to exclusion from the trial (e.g. Diabetes mellitus, malignant melanoma, cardiac conduction disorders, hepatic/renal insufficiency.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RA with drug<br> | |
| RA without drug<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |